206 related articles for article (PubMed ID: 7851581)
21. Metachromasia of the endocervical epithelium in women treated with gonadotropin releasing hormone agonist.
Morimura M; Ishiko O; Honda KI; Sumi T; Kawamura N; Wakasa K; Haba T; Ogita S
Int J Mol Med; 2001 Sep; 8(3):319-21. PubMed ID: 11494062
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
[TBL] [Abstract][Full Text] [Related]
23. Tissue differences but limited sex steroid responsiveness of c-fos and c-jun in human fibroids and myometrium.
Gustavsson I; Englund K; Faxén M; Sjöblom P; Lindblom B; Blanck A
Mol Hum Reprod; 2000 Jan; 6(1):55-9. PubMed ID: 10611261
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
25. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
[TBL] [Abstract][Full Text] [Related]
26. Effect of Decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium.
Pasqualini JR; Cornier E; Grenier J; Vella C; Schatz B; Netter A
Fertil Steril; 1990 Jun; 53(6):1012-7. PubMed ID: 2140991
[TBL] [Abstract][Full Text] [Related]
27. Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas.
Uemura T; Mori J; Yoshimura Y; Minaguchi H
Asia Oceania J Obstet Gynaecol; 1991 Dec; 17(4):315-20. PubMed ID: 1724899
[TBL] [Abstract][Full Text] [Related]
28. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
29. Decreased prolactin secretion by explant cultures of fibroids from women treated with a gonadotropin-releasing hormone agonist.
Rein MS; Friedman AJ; Heffner LJ
J Clin Endocrinol Metab; 1990 Jun; 70(6):1554-8. PubMed ID: 2112150
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
31. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Fertil Steril; 1984 Oct; 42(4):644-6. PubMed ID: 6436065
[No Abstract] [Full Text] [Related]
32. [Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone concentrations].
Wu J; Cheng Y
Zhonghua Fu Chan Ke Za Zhi; 1995 Oct; 30(10):603-7. PubMed ID: 8745507
[TBL] [Abstract][Full Text] [Related]
33. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
34. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
35. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium.
Sadan O; van Iddekinge B; van Gelderen CJ; Savage N; Becker PJ; van der Walt LA; Robinson M
Ann Clin Biochem; 1987 May; 24 ( Pt 3)():263-7. PubMed ID: 3606010
[TBL] [Abstract][Full Text] [Related]
36. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure.
Bozzini N; Rodrigues CJ; Petti DA; Bevilacqua RG; Gonçalves SP; Pinotti JA
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):330-4. PubMed ID: 12716317
[TBL] [Abstract][Full Text] [Related]
37. Estrogen and progesterone receptors in uterine leiomyomas.
Marugo M; Centonze M; Bernasconi D; Fazzuoli L; Berta S; Giordano G
Acta Obstet Gynecol Scand; 1989; 68(8):731-5. PubMed ID: 2631544
[TBL] [Abstract][Full Text] [Related]
38. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
Rolland R; Franssen AM; Willemsen WN; Corbey RS
Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
[No Abstract] [Full Text] [Related]
39. Uterine leiomyoma: treatment with LHRH agonist.
Maheux R; Lemay A
Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
[No Abstract] [Full Text] [Related]
40. Immunoexpression of Steroid Hormone Receptors and Proliferation Markers in Uterine Leiomyoma and Normal Myometrial Tissues from the Miniature Pig, Sus scrofa.
Mozzachio K; Moore AB; Kissling GE; Dixon D
Toxicol Pathol; 2016 Apr; 44(3):450-7. PubMed ID: 26692562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
